Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 5:40-46 (2008)
© 2008 The American Thoracic Society
doi: 10.1513/pats.200704-053VS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Léguillette, R.
Right arrow Articles by Lauzon, A.-M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Léguillette, R.
Right arrow Articles by Lauzon, A.-M.

Molecular Mechanics of Smooth Muscle Contractile Proteins in Airway Hyperresponsiveness and Asthma

Renaud Léguillette1 and Anne-Marie Lauzon2

1 University of Calgary, Faculty of Veterinary Medicine, Calgary, Alberta, Canada; and 2 Meakins-Christie Laboratories, McGill University, Montréal, Québec, Canada

Correspondence and requests for reprints should be addressed to Anne-Marie Lauzon, Ph.D., Meakins-Christie Laboratories, McGill University, 3626 St-Urbain street, Montréal, PQ, H2X 2P2 Canada. E-mail: anne-marie.lauzon{at}mcgill.ca

ABSTRACT

Airway hyperresponsiveness (AH) is a hallmark of asthma. The dynamics of the airway smooth muscle (SM) contraction, rather than its force-generating capacity, have been postulated to be key features of AH. Two mechanisms were proposed whereby an increased velocity of shortening (Vmax) of the airway SM leads to excessive bronchoconstriction. The first mechanism involves a greater Vmax during the initial portion of contraction, whereas the second mechanism implicates a greater Vmax after muscle stretches, such as after each tidal breath. This review focuses on the components of the contractile apparatus that have so far been reported to enhance the mechanics of the myosin molecular motor, thus leading to a greater Vmax. A greater activation of myosin, via increased phosphorylation of its regulatory light chain (LC20) by myosin light chain kinase, correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells. However, poor correlations between these two parameters have also been reported in other models. A greater expression of the fast SM myosin heavy chain isoform [(+)insert or SM-B] also correlates with the greater Vmax measured in models of AH and in human asthmatic bronchial SM cells. However, the (+)insert isoform can only explain a twofold increase in Vmax, as extrapolated from its velocity of actin filament propulsion in the in vitro motility assay. Further considerations are given to the combination of these two factors with other components of the contractile machinery, thereby leading to the enhancement of airway SM function.

Key Words: thin filament • thick filament • myosin • actin • phosphorylation

The role of smooth muscle (SM) in normal airways is not clear (1, 2) but it is widely accepted that its function is altered in asthma (3). Asthmatic airways exhibit two distinctive abnormalities that can be at least partly attributed to SM dysfunction. First, patients with asthma show bronchial hyperresponsiveness, which is the occurrence of excessive bonchoconstriction in response to a given dose of agonist. This is also reflected in a fall in forced expiratory volume in 1 second (FEV1) that occurs at much lower doses of agonists than in normal subjects, and in an agonist dose–response curve that shows no maximum or plateau (4). A second feature of asthma, that is likely due to abnormalities in SM, is the inability of deep inspirations to reverse acutely induced bronchoconstriction (5), and in some cases to even worsen the symptoms (6). Although it is now accepted that airway SM mass is increased in fatal asthma, it may not be the case for nonfatal asthma. Indeed, using techniques that allow the distinction between smooth muscle cells and extracellular matrix, Thomson and coworkers reported no differences in smooth muscle mass between subjects with asthma and control subjects (7, 8). Thus, alterations in properties intrinsic to the SM most probably explain the abnormalities of airway constriction in asthma.

Intuitively, a stronger muscle should lead to a greater extent of shortening in response to a contractile stimulus, and to a greater airway narrowing. Thus, force generation in response to agonist stimulation was the first mechanical parameter of SM to be tested with respect to airway responsiveness. Surprisingly, there was no consensus attained among studies and it was concluded that isometric force is not different between asthmatic and normal airway SM (9–12). However, the difficulty in reporting force measurements relative to optimal length and normalized to SM volume or mass should be taken into account when reviewing this literature. Despite those limitations, it has been generally accepted that bronchial SM contractility is unchanged in asthma and that bronchospasms probably result from excessive stimulation. More recently, however, the dynamic behavior (velocity of shortening) of airway SM was suggested to be a key feature of the exaggerated airway narrowing observed in asthma. This proposal followed the multiple reports of the increased velocity of SM shortening (Vmax) observed in airway hyperresponsiveness and asthma. That is, a greater Vmax has been observed ex vivo in airways of the allergic dog model (13, 14) and allergic mouse model (15) stimulated electrically, in innate airway hyperresponsiveness in mouse stimulated with metacholine (16) and in rats stimulated electrically (17) or with metacholine (18), in sensitized human bronchi (19), and in single SM cells from asthmatic human bronchi (20) stimulated electrically.

Two mechanisms have been suggested to explain how an increased Vmax could lead to airway hyperresponsiveness. The first theory emerged from the measurements performed by Stephens and coworkers, who showed in their allergic dog model that the development of Vmax occurs during the first 2 seconds of a 10-second contraction (14, 21). They suggested that the remaining of the contraction was handled by more slowly cycling cross-bridges, so-called latch-bridges. Similarly, they showed in human bronchial SM cells that 90% of the shortening occurs during the first 1.5 seconds of the contraction (20). From those observations, they suggested that a faster contractile machinery would lead to a greater extent of shortening during the first few seconds of active contraction, thus a greater airway narrowing (14, 21). The second theory suggested to explain how a greater Vmax could lead to airway hyperresponsiveness emerged from the more recent advances on the effects of deep inspiration. When subjects without asthma are prevented from taking deep breaths, they experience airway hyperresponsiveness similar to that of subjects with asthma (22). Thus, it has been hypothesized that airway SM stretching by tidal inflation or deep breaths decrease airway resistance in normal lungs but not in those of patients with asthma (5, 22). Modern imaging techniques have revealed that airways of patients with asthma also dilate upon stretching but that this dilation is transient, as asthmatic airways quickly narrow back to their initial diameter (23). These results suggest that asthmatic airway SM can shorten faster than normal SM after a stretch. This rapid reconstriction might maintain asthmatic airway SM in a more constricted state because it would have time to shorten significantly between each breath, which would counteract the relaxing effect of tidal breathing (24, 25). Indeed, it is thought that the degree of airway narrowing is an equilibrium state that depends on the rate of acto-myosin cross-bridge interaction versus the rate of stretch imposed on airway SM by tidal breathing (26). Therefore, a greater rate of SM shortening is more likely to compensate for the disruptions of the cross-bridges induced by oscillatory stretches (24–27).

The proteins of the contractile apparatus are responsible for force and movement of muscle and dictate the resulting mechanical properties of the airway SM. Therefore, this article will focus on the molecular mechanics of the proteins of the contractile apparatus in the context of asthma and airway hyperresponsiveness. Specifically, we will address the expression and function of the various contractile proteins found in airway SM.

PROTEINS OF THE CONTRACTILE APPARATUS

The SM contractile apparatus is composed of thick and thin filaments. The thick filaments are constituted of myosin molecules, while the thin filaments comprise {alpha}– and {gamma}–actin; the regulatory proteins tropomyosin, caldesmon and calponin; and potentially, SM22 (Figure 1). There would be no movement possible without the molecular motor myosin. Molecular motors are mechanoenzymes that can transform the chemical energy liberated from ATP hydrolysis into mechanical work. Myosin is a hexameric protein made up of two heavy chains (~ 200 kD), each noncovalently associated with a pair of light chains, the essential (17 kD) and the regulatory (20 kD) light chains (Figure 2) (28–30).


Figure 1
View larger version (33K):
[in this window]
[in a new window]

  		Figure 1. Smooth muscle myosin thick filament composed of myosin heavy chains and light chains (essential and regulatory) and thin filament composed of actin, tropomyosin, caldesmon, and calponin. P: phosphorylated myosin head. Modified by permission from Reference 108.

 

Figure 2
View larger version (31K):
[in this window]
[in a new window]

  		Figure 2. Schematic illustrating the structure of the smooth muscle myosin heavy and light chains. The insert is shown in red. The (–)insert loop is shown in blue like the rest of the heavy chain. The regulatory light chain is shown in yellow and the essential light chain is shown in pink. The model was generated using the coordinates of Rayment (107) using Insight 2, v. 95.0 (MSI; San Diego, CA). Modified by permission from References 53, 109, 110.

 
Smooth Muscle Myosin Heavy Chains
The head, or the N-terminus, of the SM myosin heavy chain (SMMHC) contains the ATP and the actin-binding domains (Figure 2). The tail, or the C-terminus, of the SMMHC forms an elongated coiled-coil {alpha}-helix involved in self-association and thick-filament formation (Figure 2) (31). There are four known isoforms of the SMMHC that are generated by alternative splicing of a single gene located on chromosome 16p13.13–13.12 in humans (32). At the C-terminus, the isoforms differ by distinct sequences of 43 (SM-1) or 9 (SM-2) amino acids yielding a longer (204 kD) and a shorter (200 kD) tailed myosin, respectively (33, 34). The shorter sequence of SM2 results from the insertion of an exon that encodes a stop codon (Figure 3) (35, 36). The SMMHC assembles as dimers and although SM-1 and SM-2 heterodimers can be cross-linked in vitro, cells seem to preferentially contain homodimers (31). The content of SM-1 and SM-2 varies with tissues and was shown in many species to shift during maturation of SM cells (37, 38). However, there are no differences in SM-1 and SM-2 expression between human adult and infant bronchial or tracheal tissue (39). It is also believed that the expression of the SM-1 and SM-2 isoforms is not altered in asthma (40). Nonetheless, the function of SM-1 and SM-2 is still unclear. Indeed, no differences were observed in their velocity of actin filament propulsion ({nu}max) as measured by the in vitro motility assay (31, 41) or in the Vmax measured in tissues with different SM-1:SM-2 content (42–44). However, the filament assembly of SM-1 and SM-2 differ in vitro (31), which might confer functional differences at the whole muscle level. This will require further investigation.


Figure 3
View larger version (26K):
[in this window]
[in a new window]

  		Figure 3. Schematic illustrating the alternative splicing of the mRNA that occurs in SMMHC at the 5' and 3' ends. Inclusion of exon 5b generates the (+)insert isoform, whereas inclusion of exon 41, encoding a stop codon, generates the shorter (200-kD) SM2 isoform. The amino acid sequence of the insert is indicated for human myosin. Modified by permission from References 50 and 109.

 
At the N-terminus, two SMMHC isoforms are generated by alternative splicing of a 21–base pair exon, between exon 5a and exon 6 (Figures 2 and 3) (45, 46). These isoforms differ by the presence [(+)insert] or absence [(–)insert] of a 7–amino acid insert in the flexible surface loop 1. The (+) and (–)insert SMMHC isoforms are also commonly referred to as SM-B and SM-A, respectively. The expression of (+) and (–)insert isoforms is tissue specific. Indeed, studies have shown, at both the mRNA and protein levels, that the rapidly contracting phasic muscle expresses more of the (+)insert isoform, whereas the slowly contracting tonic muscle expresses more of the (–)insert isoform (47–49). The human (+)insert isoform sequence was recently determined and confirmation was obtained of its greater expression in human phasic than tonic SM, while the levels in the trachea were intermediate (50). There is growing interest in the study of these N-terminus isoforms because the sole addition of the 7–amino acid insert alters drastically the myosin molecular mechanics.

In addition to a twofold greater ATPase activity, the (+)insert isoform has a twofold greater {nu}max than the (–)insert isoform (51–53). This has been further dissected using a laser trap assay to measure the force and displacement generated by single myosin molecules. Whereas both myosin isoforms produced similar unitary force and displacement, the presence of the insert decreased the attachment time to actin after the power stroke by approximately twofold (53). The net effect of this decrease in time of attachment of myosin to actin is to increase the cross-bridge cycling rate. Furthermore, it was shown that both the time of MgADP release and the time for MgATP binding were decreased in presence of the insert (53). Thus, the insert in loop 1 controls the rate of MgADP release, which is itself the rate-limiting step of unloaded Vmax (54, 55). How exactly the insert acts is still unknown, but it has been suggested that its presence increases the flexibility of the loop above the nucleotide-binding pocket, which facilitates the in and out movement of the nucleotides (56).

Smooth Muscle Myosin Light Chains
In SM, phosphorylation of the regulatory light chain LC20 is responsible for myosin activation (57) (Figure 2). This phosphorylation is accomplished by myosin light chain kinase (MLCK), which is itself activated by the calcium–calmodulin complex. Dephosphorylation is accomplished by myosin light chain phosphatase (MLCP). Experiments using the in vitro motility assay have shown that there is no movement without myosin LC20 phosphorylation (58). There are two isoforms of the LC20, but no functional differences are known between them. The role of the essential light chain LC17, on the other hand, is still poorly understood. It has been shown in skeletal muscle that removal of the LC17 decreases {nu}max as well as its molecular force generation, as measured in the micro-needle assay (59). Exactly how the LC17 exerts this function is unclear, but it is believed to strengthen the myosin lever arm (59). Two isoforms of the LC17 (LC17a and LC17b) are also generated from a single gene by alternative splicing of the mRNA (60–62). Any combination of the heavy and light chain isoforms is possible (Figure 3). Some studies have shown a preferential expression of the acidic LC17a isoform in conjunction with the (+)insert myosin heavy chain in rapidly contracting phasic muscle and of the basic LC17b isoform with the (–)insert myosin heavy chain in slowly contracting tonic muscle (61, 63, 64). However, other studies have shown a lack of correlation between contractility and LC17 isoform expression (61, 63, 65). More recently, uncorrelated expression of LC17 isoforms and SMMHC isoforms have been reported in animal models of airway hyperresponsiveness (66) and in bladder obstruction (67).

Because the discovery of the LC17 isoforms preceded that of the (+) and (–)insert SMMHC isoforms, it has been thought for a long time that the LC17 isoformic composition was an important determinant of the velocity of SM shortening. More recently, however, in an elegant study, Rovner and coworkers produced myosin molecules in which they exchanged the light chain isoforms and found that it was necessary and sufficient to express the insert in the heavy chain to double {nu}max (52). Furthermore, studies performed at the single cell level showed no correlation between LC17 isoform expression and the unloaded shortening velocity (43, 68). Altogether these results suggest that the SMMHC isoforms, rather than the LC17 isoforms, are the major determinants of the velocity of SM contraction.

Thin Filament Proteins
Filamentous actin is formed of a double-helix of polymers of globular actin. Contractile SM actin isoforms include the {alpha}– and {gamma}–isoforms, also referred to as vascular and enteric, respectively (69). The content in actin isoforms varies during development, but reaches a tissue-specific distribution in adults. These isoforms of actin have a very similar structure, differing only by four residues, mainly toward the N-terminus (70). The difference in function of the SM actin isoforms is poorly understood. Mice in which the {alpha}–SM actin gene had been knocked out showed abnormalities of vascular SM contraction and blood pressure regulation (71). Unfortunately, their airway SM function has not been studied. The role of the isoforms of actin does not seem to be mechanical because no difference is observed in {nu}max and in loaded velocity of actin propulsion in the in vitro motility assay, when exchanging SM actin for skeletal actin (72). They are, however, believed to be implicated in the regulation of contraction, along with the multiple actin decorating proteins.

The actin-binding proteins regulate the cross-bridge enzymatic and mechanical properties. Tropomyosin and caldesmon form continuous filaments that spiral around the actin double helices. Because of this continuous structure, they are though to transmit regulatory information to several myosin molecules simultaneously, allowing them to act cooperatively (reviewed in Reference 69). When bound to actin, tropomyosin is known to increase {nu}max (58), whereas caldesmon decreases both {nu}max and the myosin ATPase activity (58, 73). The inhibitory effect of caldesmon is thought to be reversed by the binding of Ca2+-calmodulin to caldesmon or by its phosphorylation (69). Caldesmon can also bind to actin via its N-terminus, but the function of this attachment remains unknown (reviewed in Reference 69). Similarly to caldesmon, calponin has been shown to inhibit myosin ATPase activity and to be regulated by phosphorylation (74). The function of calponin seems to be different depending on if it is in a phasic or a tonic muscle (75). Finally, SM22, which is ubiquitously expressed in SM, is also believed to be an actin binding protein, but its function remains unknown (76, 77). The expression and function of actin isoforms and all these actin regulatory proteins have been poorly addressed in airway hyperresponsiveness and asthma.

SMOOTH MUSCLE MOLECULAR AND TISSUE MECHANICS

Because myosin is the molecular motor that drives muscle contraction, it is not surprising that it has received enormous attention not only for its function in normal muscle mechanics, but also for its potential role in diseases. The remainder of this article will focus on the recent progress made in understanding the molecular and tissue mechanics of the SM myosin isoforms as well as their activation by MLCK.

Myosin Isoform Expression and Function in Health and in Models of Disease
A clear correlation between the (+)insert isoform expression and increased Vmax has been reported in rabbit vascular SM (78), in the opossum esophagus (64), and in the rabbit urinary system (79). At the cellular level, a clear relationship between the (+)insert content and Vmax has also been observed in the rabbit stomach, with the cells of the antrum expressing more of the (+)insert isoform and contracting at a faster Vmax than the cells from the fundus (80). In canine airways, a correlation between the (+)insert isoform expression and Vmax has also been reported, with the trachea expressing more of the (+)insert isoform and contracting to a greater extent and with a greater Vmax (81, 82). More recently, this relationship was also shown to be maintained at the molecular level. That is, myosin was purified from multiple rat organs and it was shown that the expression in (+)insert isoform and {nu}max were greater in the rapidly contracting phasic organs than in the slowly contracting tonic organs (50).

Many studies have shown that SMMHC isoform expression is altered in disease. This has been studied in models of bladder (reviewed in Reference 79) and intestinal obstruction (83), in models of pulmonary hypertension (84), as well as in models of asthma (66). The bladder and intestinal hypertrophic tissues showed decreases in (+)insert isoform expression along with decreases in rate of force development and Vmax, respectively (79). Furthermore, the changes observed in (+)insert expression in bladder hypertrophy, were shown to be due to changes in cell phenotype and not to the appearance of new cells (85). Treatment was shown to reverse the myosin isoform expression back to normal (86). Together these results demonstrate the ability of SM cells to adapt to their environmental conditions.

The expression of the (+)insert isoform was also addressed in the Fisher (F344) and Lewis rat model of airway hyperresponsiveness (66). A 44% greater expression in (+)insert relative to total SMMHC was found in the hyperresponsive Fisher rat trachea compared with the normoresponsive Lewis rat. This greater expression of the (+)insert isoform is in good agreement with the 46% greater Vmax of the Fisher rats measured at the muscle strip level (17), the greater rate of airway constriction measured in explants (18), and with preliminary data showing an approximately 20% greater {nu}max measured at the molecular level (87). At the whole animal level, the (+)insert isoform knockout mouse (88) exhibits an approximately 18% increase in time to peak airway resistance compared with the wild-type mice (89). Altogether these data highly suggest that the (+)insert isoform expression affects the velocity of airway SM shortening.

Myosin Activation in Health and in Models of Disease
Another factor that can affect airway SM shortening velocity is the level of activation of myosin light chain LC20. A greater level of phosphorylation has been associated with increased Vmax in a dog model of allergic airway hyperresponsiveness (21, 90). This greater phosphorylation level was due to a greater content in MLCK. This has also been studied in a model of innate airway hyperresponsiveness: the hyperresponsive Fisher F344 rats exhibit greater levels of phosphorylation of the LC20 than the Lewis rats (66) and this is also associated with a greater Vmax (17). A greater calcium mobilization was also observed in the F344 rats (91), thus leading to greater LC20 phosphorylation (66). However, the specific mechanism by which a greater phosphorylation level would enhance SM contractility remains unknown and controversial. For a given dose of agonist, a greater level of phosphorylation will lead to greater tension development (66). However, a clear link between phosphorylation level and Vmax remains to be established. Indeed, whereas multiple studies found a good correlation between myosin LC20 phosphorylation and Vmax (92–95), several others reported no correlation (96–99). The dissociation between Vmax and phosphorylation seems to be greatest early in the contraction in the case of tracheal smooth muscle (96).

Traditionally, greater levels of LC20 phosphorylation have been attributed to greater MLCK content but more recently the focus has turned to inhibition of MLCP (100). This mechanism is referred to as Ca2+ sensitization. This mechanism is regulated either directly by the monomeric protein RhoA and Rho-kinase or by phosphorylation of the MLCP inhibitor CPI-17 (100). Recent studies have demonstrated increased smooth muscle contractility due to Ca2+ sensitization in models of airway hyperresponsiveness (101, 102).

Myosin Activation and (+)Insert Isoform Expression in Human Asthma
Recent studies have addressed myosin activation in human asthmatic airway SM cells. An increased MLCK mRNA accompanied the greater Vmax and greater extent of shortening observed in mild asthmatic endobronchial single SM cells (20). Others used a morphometric analysis and reported an increase in MLCK protein level without changes in phosphorylated LC20 in individuals with severe asthma, but not in those with moderate asthma (103). It has also been shown that ex vivo sensitization of human airway SM increases the expression of MLCK (104). Furthermore, in another preliminary study, an increased MLCK mRNA was also observed in endobronchial biopsies from individuals with mild asthma (87). Altogether these studies strongly suggest that MLCK expression is increased in asthma. However, as mentioned above, the relationship between LC20 phosphorylation and Vmax has been challenged (96–99), so the role of MLCK in human airway hyperesponsiveness needs to be further addressed.

Because the human myosin isoforms have only recently been sequenced (50), and because of the difficulty in obtaining human bronchial tissues, the studies addressing the expression of the (+)insert isoform in human airways are only beginning. In a preliminary study, a 2.4-fold greater (+)insert myosin isoform mRNA expression was reported in individuals with mild asthma compared with control subjects (87). Given the correlations previously established between the (+)insert myosin isoform expression and {nu}max measured at the molecular level and Vmax measured at the muscle strip level, as well as its increased expression in several models of disease, the (+)insert isoform is likely to be one of the key contributors to airway hyperresponsiveness and asthma.

Future Directions
Multiple factors are likely to interact to enhance the contractile properties of asthmatic airway SM, and their role, alone and in conjunction, needs further investigation. Very little research has been done with respect to the potential involvement of the actin isoforms and actin regulatory proteins. One such example is SM22, which was recently shown to be increased by 2.2-fold at the mRNA level in bronchial biopsies from individuals with mild asthma (87). However, the mechanical function of SM22 remains completely unknown (105). It is even uncertain whether SM22 really acts as an actin-binding protein, although it is known to attach to actin. It is also uncertain whether its expression is exclusive to the SM cells (106). Furthermore, the implications of the various combinations of the head and tail myosin isoforms (SM-A and SM-B with SM-1 and SM-2), as well as the combinations with various light chain isoforms (LC17a and LC17b), still need to be assessed, and the functional impact in tissue will need to be weighted against regulation by LC20 phosphorylation. Obviously, more research is needed to address the function of all contractile proteins in normal contraction as well as in airway hyperresponsiveness and asthma. A major advancement will certainly come from the understanding of the mechanisms of regulation of the SMMHC isoform expression. Indeed, can factors such as inflammation, oxidative stress, and maturation regulate the alternative splicing of the SMMHC mRNA during health and disease? These issues have not been clarified, and thus future work is necessary.

CONCLUSIONS

Vmax has been shown to be increased in numerous models of airway hyperresponsiveness as well as in human asthma. A greater phosphorylation of the LC20 correlates with an increased Vmax in models of AH and in human asthmatic bronchial SM cells. However, a poor correlation between these two parameters has also been reported in other models. A greater expression of the fast (+)insert myosin isoform also correlates with the greater Vmax measured in models of AH and in human asthmatic bronchial SM cells. However, the contribution of the (+)insert isoform can be of at most a twofold increase in Vmax, as extrapolated from its velocity of actin filament propulsion in the in vitro motility assay. These two factors most probably combine to increase Vmax further. Clearly, more research is needed to determine if and how other parameters of the contractile apparatus also contribute to the enhancement of Vmax in airway hyperresponsiveness and asthma.

FOOTNOTES

Conflict of Interest Statement: Neither author has a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

(Received in original form April 30, 2007; accepted in final form August 3, 2007)

REFERENCES

  1. Seow CY, Fredberg JJ. Historical perspective on airway smooth muscle: the saga of a frustrated cell. J Appl Physiol 2001;91:938–952.[Abstract/Free Full Text]
  2. Mitzner W. Airway smooth muscle: the appendix of the lung. Am J Respir Crit Care Med 2004;169:787–790.[Free Full Text]
  3. Martin JG, Duguet A, Eidelman DH. The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease. Eur Respir J 2000;16:349–354.[Abstract]
  4. Woolcock AJ, Anderson SD, Peat JK, Du Toit JI, Zhang YG, Smith CM, Salome CM. Characteristics of bronchial hyperresponsiveness in chronic obstructive pulmonary disease and in asthma. Am Rev Respir Dis 1991;143:1438–1443.[Medline]
  5. Fish JE, Ankin MG, Kelly JF, Peterman VI. Regulation of bronchomotor tone by lung inflation in asthmatic and nonasthmatic subjects. J Appl Physiol 1981;50:1079–1086.[Abstract/Free Full Text]
  6. Lim TK, Pride NB, Ingram RH Jr. Effects of volume history during spontaneous and acutely induced air-flow obstruction in asthma. Am Rev Respir Dis 1987;135:591–596.[Medline]
  7. Thomson RJ, Bramley AM, Schellenberg RR. Airway muscle stereology: implications for increased shortening in asthma. Am J Respir Crit Care Med 1996;154:749–757.[Abstract]
  8. Thomson RJ, Schellenberg RR. Increased amount of airway smooth muscle does not account for excessive bronchoconstriction in asthma. Can Respir J 1998;5:61–62.[Medline]
  9. Bai TR. Abnormalities in airway smooth muscle in fatal asthma: a comparison between trachea and bronchus. Am Rev Respir Dis 1991;143:441–443.[Medline]
  10. Whicker SD, Armour CL, Black JL. Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agonists. Pulm Pharmacol 1988;1:25–31.[CrossRef][Medline]
  11. Thomson NC. In vivo versus in vitro human airway responsiveness to different pharmacologic stimuli. Am Rev Respir Dis 1987;136:S58–S62.[Medline]
  12. Bjorck T, Gustafsson LE, Dahlen SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 1992;145:1087–1091.[Medline]
  13. Antonissen LA, Mitchell RW, Kroeger EA, Kepron W, Tse KS, Stephens NL. Mechanical alterations of airway smooth muscle in a canine asthmatic model. J Appl Physiol 1979;46:681–687.[Free Full Text]
  14. Jiang H, Rao K, Halayko AJ, Kepron W, Stephens NL. Bronchial smooth muscle mechanics of a canine model of allergic airway hyperresponsiveness. J Appl Physiol 1992;72:39–45.[Abstract/Free Full Text]
  15. Fan T, Yang M, Halayko A, Mohapatra SS, Stephens NL. Airway responsiveness in two inbred strains of mouse disparate in IgE and IL-4 production. Am J Respir Cell Mol Biol 1997;17:156–163.[Abstract/Free Full Text]
  16. Duguet A, Biyah K, Minshall E, Gomes R, Wang CG, Taoudi-Benchekroun M, Bates JH, Eidelman DH. Bronchial responsiveness among inbred mouse strains: role of airway smooth-muscle shortening velocity. Am J Respir Crit Care Med 2000;161:839–848.[Abstract/Free Full Text]
  17. Blanc FX, Coirault C, Salmeron S, Chemla D, Lecarpentier Y. Mechanics and crossbridge kinetics of tracheal smooth muscle in two inbred rat strains. Eur Respir J 2003;22:227–234.[Abstract/Free Full Text]
  18. Wang CG, Almirall JJ, Dolman CS, Dandurand RJ, Eidelman DH. In vitro bronchial responsiveness in two highly inbred rat strains. J Appl Physiol 1997;82:1445–1452.[Abstract/Free Full Text]
  19. Mitchell RW, Ruhlmann E, Magnussen H, Leff AR, Rabe KF. Passive sensitization of human bronchi augments smooth muscle shortening velocity and capacity. Am J Physiol 1994;267:L218–L222.[Medline]
  20. Ma X, Cheng Z, Kong H, Wang Y, Unruh H, Stephens NL, Laviolette M. Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol 2002;283:L1181–L1189.[Abstract/Free Full Text]
  21. Jiang H, Rao K, Halayko AJ, Liu X, Stephens NL. Ragweed sensitization-induced increase of myosin light chain kinase content in canine airway smooth muscle. Am J Respir Cell Mol Biol 1992;7:567–573.[Medline]
  22. Skloot G, Permutt S, Togias A. Airway hyperresponsiveness in asthma: a problem of limited smooth muscle relaxation with inspiration. J Clin Invest 1995;96:2393–2403.[Medline]
  23. Brown RH, Scichilone N, Mudge B, Diemer FB, Permutt S, Togias A. High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. Am J Respir Crit Care Med 2001;163:994–1001.[Abstract/Free Full Text]
  24. Solway J, Fredberg JJ. Perhaps airway smooth muscle dysfunction contributes to asthmatic bronchial hyperresponsiveness after all. Am J Respir Cell Mol Biol 1997;17:144–146.[Free Full Text]
  25. Gunst SJ. Contractile force of canine airway smooth muscle during cyclical length changes. J Appl Physiol 1983;55:759–769.[Abstract/Free Full Text]
  26. Fredberg JJ, Inouye DS, Mijailovich SM, Butler JP. Perturbed equilibrium of myosin binding in airway smooth muscle and its implications in bronchospasm. Am J Respir Crit Care Med 1999;159:959–967.[Abstract/Free Full Text]
  27. Fredberg JJ, Inouye D, Miller B, Nathan M, Jafari S, Raboudi SH, Butler JP, Shore SA. Airway smooth muscle, tidal stretches, and dynamically determined contractile states. Am J Respir Crit Care Med 1997;156:1752–1759.[Abstract/Free Full Text]
  28. Berg JS, Powell BC, Cheney RE. A millennial myosin census. Mol Biol Cell 2001;12:780–794.[Abstract/Free Full Text]
  29. Loukianov E, Loukianova T, Periasamy M. Myosin heavy chain isoforms in smooth muscle. Comp Biochem Physiol B Biochem Mol Biol 1997;117:13–18.[CrossRef][Medline]
  30. Morano I. Tuning smooth muscle contraction by molecular motors. J Mol Med 2003;81:481–487.[CrossRef][Medline]
  31. Rovner AS, Fagnant PM, Lowey S, Trybus KM. The carboxyl-terminal isoforms of smooth muscle myosin heavy chain determine thick filament assembly properties. J Cell Biol 2002;156:113–123.[Abstract/Free Full Text]
  32. Deng Z, Liu P, Marlton P, Claxton DF, Lane S, Callen DF, Collins FS, Siciliano MJ. Smooth muscle myosin heavy chain locus (myh11) maps to 16p13.13-p13.12 and establishes a new region of conserved synteny between human 16p and mouse 16. Genomics 1993;18:156–159.[CrossRef][Medline]
  33. Eddinger TJ, Murphy RA. Two smooth muscle myosin heavy chains differ in their light meromyosin fragment. Biochemistry 1988;27:3807–3811.[CrossRef][Medline]
  34. Kawamoto S, Adelstein RS. Characterization of myosin heavy chains in cultured aorta smooth muscle cells: a comparative study. J Biol Chem 1987;262:7282–7288.[Abstract/Free Full Text]
  35. Babij P, Periasamy M. Myosin heavy chain isoform diversity in smooth muscle is produced by differential rna processing. J Mol Biol 1989;210:673–679.[CrossRef][Medline]
  36. Nagai R, Kuro-o M, Babij P, Periasamy M. Identification of two types of smooth muscle myosin heavy chain isoforms by cdna cloning and immunoblot analysis. J Biol Chem 1989;264:9734–9737.[Abstract/Free Full Text]
  37. Cavaille F, Janmot C, Ropert S, d'Albis A. Isoforms of myosin and actin in human, monkey and rat myometrium. Comparison of pregnant and non-pregnant uterus proteins. Eur J Biochem 1986;160:507–513.[Medline]
  38. Mohammad MA, Sparrow MP. The heavy-chain stoichiometry of smooth muscle myosin is a characteristic of smooth muscle tissues. Aust J Biol Sci 1988;41:409–419.[Medline]
  39. Mohammad MA, Sparrow MP. The distribution of heavy-chain isoforms of myosin in airways smooth muscle from adult and neonate humans. Biochem J 1989;260:421–426.[Medline]
  40. De Marzo N, Di Blasi P, Boschetto P, Mapp CE, Sartore S, Picotti G, Fabbri LM. Airway smooth muscle biochemistry and asthma. Eur Respir J Suppl 1989;6:473s–476s.[Medline]
  41. Kelley CA, Sellers JR, Goldsmith PK, Adelstein RS. Smooth muscle myosin is composed of homodimeric heavy chains. J Biol Chem 1992;267:2127–2130.[Abstract/Free Full Text]
  42. Packer CS, Griffith SL, Roepke JE, Meiss RA, Rhoades RA. Myosin heavy chain isoform patterns do not correlate with force-velocity relationships in pulmonary arterial compared with systemic arterial smooth muscle. Adv Exp Med Biol 1991;304:397–402.[Medline]
  43. Sherwood JJ, Eddinger TJ. Shortening velocity and myosin heavy- and light-chain isoform mrna in rabbit arterial smooth muscle cells. Am J Physiol Cell Physiol 2002;282:C1093–C1102.[Abstract/Free Full Text]
  44. Upadhya A, Samuel M, Cox RH, Bagshaw RJ, Chacko S. Characteristics of arterial myosin in experimental renal hypertension in the dog. Hypertension 1993;21:624–631.[Abstract]
  45. Babij P, Kelly C, Periasamy M. Characterization of a mammalian smooth muscle myosin heavy-chain gene: complete nucleotide and protein coding sequence and analysis of the 5' end of the gene. Proc Natl Acad Sci USA 1991;88:10676–10680.[Abstract/Free Full Text]
  46. Hamada Y, Yanagisawa M, Katsuragawa Y, Coleman JR, Nagata S, Matsuda G, Masaki T. Distinct vascular and intestinal smooth muscle myosin heavy chain mRNAs are encoded by a single-copy gene in the chicken. Biochem Biophys Res Commun 1990;170:53–58.[CrossRef][Medline]
  47. White SL, Zhou MY, Low RB, Periasamy M. Myosin heavy chain isoform expression in rat smooth muscle development. Am J Physiol 1998;275:C581–C589.[Medline]
  48. Low RB, Mitchell J, Woodcock-Mitchell J, Rovner AS, White SL. Smooth-muscle myosin heavy-chain sm-b isoform expression in developing and adult rat lung. Am J Respir Cell Mol Biol 1999;20:651–657.[Abstract/Free Full Text]
  49. White S, Martin AF, Periasamy M. Identification of a novel smooth muscle myosin heavy chain cdna: isoform diversity in the s1 head region. Am J Physiol 1993;264:C1252–C1258.[Medline]
  50. Leguillette R, Gil FR, Zitouni N, Lajoie-Kadoch S, Sobieszek A, Lauzon AM. (+)insert smooth muscle myosin heavy chain (sm-b) isoform expression in human tissues. Am J Physiol Cell Physiol 2005;289:C1277–C1285.[Abstract/Free Full Text]
  51. Kelley CA, Takahashi M, Yu JH, Adelstein RS. An insert of seven amino acids confers functional differences between smooth muscle myosins from the intestines and vasculature. J Biol Chem 1993;268:12848–12854.[Abstract/Free Full Text]
  52. Rovner AS, Freyzon Y, Trybus KM. An insert in the motor domain determines the functional properties of expressed smooth muscle myosin isoforms. J Muscle Res Cell Motil 1997;18:103–110.[CrossRef][Medline]
  53. Lauzon AM, Tyska MJ, Rovner AS, Freyzon Y, Warshaw DM, Trybus KM. A 7-amino-acid insert in the heavy chain nucleotide binding loop alters the kinetics of smooth muscle myosin in the laser trap. J Muscle Res Cell Motil 1998;19:825–837.[CrossRef][Medline]
  54. Siemankowski RF, Wiseman MO, White HD. Adp dissociation from actomyosin subfragment 1 is sufficiently slow to limit the unloaded shortening velocity in vertebrate muscle. Proc Natl Acad Sci USA 1985;82:658–662.[Abstract/Free Full Text]
  55. Spudich JA. How molecular motors work. Nature 1994;372:515–518.[CrossRef][Medline]
  56. Sweeney HL, Rosenfeld SS, Brown F, Faust L, Smith J, Xing J, Stein LA, Sellers JR. Kinetic tuning of myosin via a flexible loop adjacent to the nucleotide binding pocket. J Biol Chem 1998;273:6262–6270.[Abstract/Free Full Text]
  57. Sobieszek A. Ca-linked phosphorylation of a light chain of vertebrate smooth-muscle myosin. Eur J Biochem 1977;73:477–483.[Medline]
  58. Okagaki T, Higashi-Fujime S, Ishikawa R, Takano-Ohmuro H, Kohama K. In vitro movement of actin filaments on gizzard smooth muscle myosin: Requirement of phosphorylation of myosin light chain and effects of tropomyosin and caldesmon. J Biochem (Tokyo) 1991;109:858–866.[Abstract/Free Full Text]
  59. VanBuren P, Waller GS, Harris DE, Trybus KM, Warshaw DM, Lowey S. The essential light chain is required for full force production by skeletal muscle myosin. Proc Natl Acad Sci USA 1994;91:12403–12407.[Abstract/Free Full Text]
  60. Hasegawa Y, Morita F. Role of 17-kda essential light chain isoforms of aorta smooth muscle myosin. J Biochem (Tokyo) 1992;111:804–809.[Abstract/Free Full Text]
  61. Helper DJ, Lash JA, Hathaway DR. Distribution of isoelectric variants of the 17,000-dalton myosin light chain in mammalian smooth muscle. J Biol Chem 1988;263:15748–15753.[Abstract/Free Full Text]
  62. Nabeshima Y, Nabeshima Y, Nonomura Y, Fujii-Kuriyama Y. Nonmuscle and smooth muscle myosin light chain mRNAs are generated from a single gene by the tissue-specific alternative rna splicing. J Biol Chem 1987;262:10608–10612.[Abstract/Free Full Text]
  63. Malmqvist U, Arner A. Correlation between isoform composition of the 17 kda myosin light chain and maximal shortening velocity in smooth muscle. Pflugers Arch 1991;418:523–530.[CrossRef][Medline]
  64. Szymanski PT, Chacko TK, Rovner AS, Goyal RK. Differences in contractile protein content and isoforms in phasic and tonic smooth muscles. Am J Physiol 1998;275:C684–C692.[Medline]
  65. Sobieszek A, Jertschin P. Urea-glycerol-acrylamide gel electrophoresis of acidic low molecular weight muscle proteins: Rapid determination of myosin light chain phosphorylation in myosin, actomyosin and whole muscle samples. Electrophoresis 1986;7:417–425.[CrossRef]
  66. Gil FR, Zitouni NB, Azoulay E, Maghni K, Lauzon AM. Smooth muscle myosin isoform expression and lc20 phosphorylation in innate rat airway hyperresponsiveness. Am J Physiol 2006;291:L932–L940.
  67. Mannikarottu AS, Hypolite JA, Zderic SA, Wein AJ, Chacko S, Disanto ME. Regional alterations in the expression of smooth muscle myosin isoforms in response to partial bladder outlet obstruction. J Urol 2005;173:302–308.[Medline]
  68. Eddinger TJ, Korwek AA, Meer DP, Sherwood JJ. Expression of smooth muscle myosin light chain 17 and unloaded shortening in single smooth muscle cells. Am J Physiol Cell Physiol 2000;278:C1133–C1142.[Abstract/Free Full Text]
  69. Morgan KG, Gangopadhyay SS. Invited review: Cross-bridge regulation by thin filament-associated proteins. J Appl Physiol (Bethesda MD) 2001;91:953–962.
  70. Vandekerckhove J, Weber K. At least six different actins are expressed in a higher mammal: an analysis based on the amino acid sequence of the amino-terminal tryptic peptide. J Mol Biol 1978;126:783–802.[CrossRef][Medline]
  71. Schildmeyer LA, Braun R, Taffet G, Debiasi M, Burns AE, Bradley A, Schwartz RJ. Impaired vascular contractility and blood pressure homeostasis in the smooth muscle alpha-actin null mouse. FASEB J 2000;14:2213–2220.[Abstract/Free Full Text]
  72. Harris DE, Warshaw DM. Smooth and skeletal muscle actin are mechanically indistinguishable in the in vitro motility assay. Circ Res 1993;72:219–224.[Abstract]
  73. Haeberle JR, Trybus KM, Hemric ME, Warshaw DM. The effects of smooth muscle caldesmon on actin filament motility. J Biol Chem 1992;267:23001–23006.[Abstract/Free Full Text]
  74. Winder SJ, Walsh MP. Smooth muscle calponin. Inhibition of actomyosin mgatpase and regulation by phosphorylation. J Biol Chem 1990;265:10148–10155.[Abstract/Free Full Text]
  75. Walsh MP. Calponin–knocked out but not down! J Physiol 2000;529:517.[Abstract/Free Full Text]
  76. Shapland C, Hsuan JJ, Totty NF, Lawson D. Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein. J Cell Biol 1993;121:1065–1073.[Abstract/Free Full Text]
  77. Fu Y, Liu HW, Forsythe SM, Kogut P, McConville JF, Halayko AJ, Camoretti-Mercado B, Solway J. Mutagenesis analysis of human sm22: characterization of actin binding. J Appl Physiol 2000;89:1985–1990.[Abstract/Free Full Text]
  78. DiSanto ME, Cox RH, Wang Z, Chacko S. Nh2-terminal-inserted myosin ii heavy chain is expressed in smooth muscle of small muscular arteries. Am J Physiol 1997;272:C1532–C1542.[Medline]
  79. Chacko S, DiSanto M, Menon C, Zheng Y, Hypolite J, Wein AJ. Contractile protein changes in urinary bladder smooth muscle following outlet obstruction. Adv Exp Med Biol 1999;462:137–153.[Medline]
  80. Eddinger TJ, Meer DP. Single rabbit stomach smooth muscle cell myosin heavy chain smb expression and shortening velocity. Am J Physiol Cell Physiol 2001;280:C309–C316.[Abstract/Free Full Text]
  81. Ma X, Li W, Stephens NL. Detection of two clusters of mechanical properties of smooth muscle along the airway tree. J Appl Physiol (Bethesda MD) 1996;80:857–861.
  82. Ma X, Stephens NL. Difference in expression of myosin heavy chain head (with 7 amino acid insert) isoform between canine tracheal and bronchial smooth muscle [abstract]. Am J Respir Crit Care Med 1997;155:A370.
  83. Lofgren M, Fagher K, Wede OK, Arner A. Decreased shortening velocity and altered myosin isoforms in guinea-pig hypertrophic intestinal smooth muscle. J Physiol 2002;544:707–714.[Abstract/Free Full Text]
  84. Jones R, Steudel W, White S, Jacobson M, Low R. Microvessel precursor smooth muscle cells express head-inserted smooth muscle myosin heavy chain (sm-b) isoform in hyperoxic pulmonary hypertension. Cell Tissue Res 1999;295:453–465.[CrossRef][Medline]
  85. DiSanto ME, Stein R, Chang S, Hypolite JA, Zheng Y, Zderic S, Wein AJ, Chacko S. Alteration in expression of myosin isoforms in detrusor smooth muscle following bladder outlet obstruction. Am J Physiol Cell Physiol 2003;285:C1397–C1410.[Abstract/Free Full Text]
  86. Gomes CM, Disanto ME, Horan P, Levin RM, Wein AJ, Chacko S. Improved contractility of obstructed bladders after tadenan treatment is associated with reversal of altered myosin isoform expression. J Urol 2000;163:2008–2013.[CrossRef][Medline]
  87. Leguillette R, Laviolette M, Bergeron C, Lauzon A-M. The protein expression of the smooth muscle myosin SMB isoform, MLCK, and SM22 is upregulated in asthmatic airways and may contribute to their hypercontractility [abstract]. Proc Am Thorac Soc 2006;3:A770.
  88. Babu GJ, Loukianov E, Loukianova T, Pyne GJ, Huke S, Osol G, Low RB, Paul RJ, Periasamy M. Loss of sm-b myosin affects muscle shortening velocity and maximal force development. Nat Cell Biol 2001;3:1025–1029.[CrossRef][Medline]
  89. Tuck SA, Maghni K, Poirier A, Babu GJ, Periasamy M, Bates JHT, Leguillette R, Lauzon AM. Time course of airway mechanics of the (+)insert myosin isoform knockout mouse. Am J Respir Cell Mol Biol 2004;30:326–332.[Abstract/Free Full Text]
  90. Jiang H, Rao K, Liu X, Liu G, Stephens NL. Increased ca2+ and myosin phosphorylation, but not calmodulin activity in sensitized airway smooth muscles. Am J Physiol 1995;268:L739–L746.[Medline]
  91. Tao FC, Tolloczko B, Eidelman DH, Martin JG. Enhanced ca(2+) mobilization in airway smooth muscle contributes to airway hyperresponsiveness in an inbred strain of rat. Am J Respir Crit Care Med 1999;160:446–453.[Abstract/Free Full Text]
  92. Chitano P, Worthington CL, Jenkin JA, Stephens NL, Gyapong S, Wang L, Murphy TM. Ontogenesis of myosin light chain phosphorylation in guinea pig tracheal smooth muscle. Pediatr Pulmonol 2005;39:108–116.[CrossRef][Medline]
  93. Dillon PF, Aksoy MO, Driska SP, Murphy RA. Myosin phosphorylation and the cross-bridge cycle in arterial smooth muscle. Science 1981;211:495–497.[Abstract/Free Full Text]
  94. Hai CM, Murphy RA. Regulation of shortening velocity by cross-bridge phosphorylation in smooth muscle. Am J Physiol 1988;255:C86–C94.[Medline]
  95. Marston SB. The regulation of smooth muscle contractile proteins. Prog Biophys Mol Biol 1983;41:1–41.[CrossRef][Medline]
  96. Mitchell RW, Seow CY, Burdyga T, Maass-Moreno R, Pratusevich VR, Ragozzino J, Ford LE. Relationship between myosin phosphorylation and contractile capability of canine airway smooth muscle. J Appl Physiol 2001;90:2460–2465.[Abstract/Free Full Text]
  97. Merkel L, Gerthoffer WT, Torphy TJ. Dissociation between myosin phosphorylation and shortening velocity in canine trachea. Am J Physiol 1990;258:C524–C532.[Medline]
  98. Obara K, de Lanerolle P. Isoproterenol attenuates myosin phosphorylation and contraction of tracheal muscle. J Appl Physiol (Bethesda MD) 1989;66:2017–2022.
  99. Gerthoffer WT. Dissociation of myosin phosphorylation and active tension during muscarinic stimulation of tracheal smooth muscle. J Pharmacol Exp Ther 1987;240:8–15.[Abstract/Free Full Text]
  100. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin ii: modulated by g proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325–1358.[Abstract/Free Full Text]
  101. Chiba Y, Misawa M. The role of rhoa-mediated ca2+ sensitization of bronchial smooth muscle contraction in airway hyperresponsiveness. J Smooth Muscle Res 2004;40:155–167.[CrossRef][Medline]
  102. Sakai H, Chiba Y, Misawa M. Augmentation of endothelin-1-induced phosphorylation of cpi-17 and myosin light chain in bronchial smooth muscle from airway hyperresponsive rats. Biol Pharm Bull 2006;29:1897–1899.[CrossRef][Medline]
  103. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360–1368.[Abstract/Free Full Text]
  104. Ammit AJ, Armour CL, Black JL. Smooth-muscle myosin light-chain kinase content is increased in human sensitized airways. Am J Respir Crit Care Med 2000;161:257–263.[Abstract/Free Full Text]
  105. Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, Lu MM, Strobeck M, Yu Q, Parmacek MS. Analysis of sm22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol 2001;21:1336–1344.[Abstract/Free Full Text]
  106. Qiu P, Feng XH, Li L. Interaction of smad3 and srf-associated complex mediates tgf-beta1 signals to regulate sm22 transcription during myofibroblast differentiation. J Mol Cell Cardiol 2003;35:1407–1420.[CrossRef][Medline]
  107. Rayment I, Rypniewski WR, Schmidt-Base K, Smith R, Tomchick DR, Benning MM, Winkelmann DA, Wesenberg G, Holden HM. Three-dimensional structure of myosin subfragment-1: a molecular motor. Science 1993;261:50–58.[Abstract/Free Full Text]
  108. Hamid Q, Shannon J, Martin J, editors. Physiologic basis of respiratory disease. Hamilton (ON): BC Decker; 2005. p382.
  109. Low R, Léguillette R, Lauzon AM. (+)Insert smooth muscle myosin heavy chain (SM-B): from single molecule to human. Int J Biochem Cell Biol 2006;38:1862–1874.[CrossRef][Medline]
  110. Gil FR, Lauzon AM. Smooth muscle molecular mechanics in airway hyperresponsiveness and asthma. Can J Physiol Pharmacol 2007;85:133–140.[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Léguillette, R.
Right arrow Articles by Lauzon, A.-M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Léguillette, R.
Right arrow Articles by Lauzon, A.-M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS